Objectives Board of Directors Advisory Board Leadership Sponsors
CIB2012 CIB2011 CIB2010 ICTM 2011
Executive Committee Education Committee International Collaboration Committee Communication Committee Membership Committee
Cellular & Molecular Medicine Applied Immunology Molecular Imaging Regenerative medicine Drug development and discovery Biomaterials & Clinical Application Omics Science
ISTM Newsletter Journals
Certification and Diplomate Program Short Term Training Abroad Long Term Abroad Training Fellowship Observer-ships Abroad
Conferences Travel Grants Travel Grants for Short Term Training Abroad Travel Fellowship for Long Term Abroad Training Observer-ships Abroad Grants Excellent in Translational Medicine Award Research Grants
News Home>>News

OUtstanding works from Dr Marko-Varga team


In the postgenomic era, it has become evident that analysis of genetic and protein expression changes alone is not sufficient to understand most disease processes in e.g. cardiovascular and cancer disease. Biobanking has been identified as an important area for development and discovery of better diagnostic tools and new treatment modalities. Biobanks are developed in order to integrate the collection of clinical samples from both healthy individuals and patients and provide valuable information that will make possible improved patient care. Modern healthcare developments are intimately linked to information based on studies of patient samples from biobank archives in large scale studies. Today biobanks form important national, as well as international, networks that share and combine global resources. We have developed and validated a novel biobanking workflow process that utilizes 384-tube systems with a high speed sample array robot with unique processing principles. The 384-tube format and robotic processing is incorporated into a cancer and cardiovascular diagnostic/prognostic research program with therapeutic interventions. Our biobank practice has gained acceptance within many hospitals and research units and is based on high-density sample storage with small aliquot sample volumes. The previous standard of 5–10 mL sample volume tubes is being replaced by smaller volumes of 50–70 μL blood fractions that typically result in hundreds of thousands of aliquot fractions in 384-tube systems. Our novel biobanking workflow process is robust and well suited for clinical studies. More information can be found in CTM (http://www.clintransmed.com/content/4/1/27 )


Copyright © 2011 istmed.org All rights Reserved.  International Society for Translational Medicine

Technical support: weicheng